The Latest Cardiac and Vascular News
Immediate need to secure approximately €3.5 million to avoid insolvency at the end of June 2025 Total funding needs of around €35 million over the next 12 months Ongoing active exploration of financing options PARIS–(BUSINESS WIRE)–Regulatory News: CARMAT (FR0010907956, ALCAR), designer and developer of the world’s most advanced total artificial […]
PARIS–(BUSINESS WIRE)–Regulatory News: CARMAT (FR0010907956, ALCAR), designer and developer of the world’s most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from advanced biventricular heart failure (the “Company” or “CARMAT”), today announces its annual results for the year ending December 31, 20241. 2024 annual results […]
Recruitment of the second cohort expected to begin in H2 2025 PARIS–(BUSINESS WIRE)–Regulatory News: CARMAT (FR0010907956, ALCAR), designer and developer of the world’s most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from advanced biventricular heart failure (the “Company” or “CARMAT”), today announces that it […]
Up to 25% of advanced heart failure patients suffer from pulmonary hypertension Aeson® could potentially become a standard treatment for these thousands of patients, both as a bridge-to-transplant and destination therapy February 17, 2025 01:00 AM Eastern Standard Time PARIS–(BUSINESS WIRE)–Regulatory News: “In our experience with patients suffering from pulmonary […]
PARIS–(BUSINESS WIRE)–Regulatory News: CARMAT (FR0010907956, ALCAR), designer and developer of the world’s most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from advanced biventricular heart failure (the “Company” or “CARMAT”), today announces that it has passed the milestone of 100 implants of its Aeson® artificial […]
Over 90 patients have received the Aeson® artificial heart since the first implant in 2013, including 42 in 2024. 2024 Sales of €7 million (a 2.5-fold increase vs 2023). Cash burn reduced by over 20% vs 2023. 50 hospitals trained in Aeson® implants internationally1. Successful first “Aeson® User Meeting” and […]
Buy-back by CARMAT of 2 million shares from Airbus for a symbolic sum of 1 euro. The shares so bought-back will be allocated to the repayment of the Company’s financial debt, via their use in the ongoing equitization of the loan contracted with the European Investment Bank, thus reducing the […]
This capital increase will be carried out through a public offering without preferential subscription rights and with a 7 trading days priority period, on an irreducible and reducible basis, for the benefit of CARMAT’s shareholders The initial amount of the capital increase may be increased up to €11.8 million in […]
Half-year sales of €3.3 million, exceeding 2023 full-year sales 20 implants of the Aeson® artificial heart performed in the first half of 2024 17% cash-burn1 reduction compared to the first half of 2023 2024 anticipated annual sales of €8 to €12 million Other 2024 operational objectives on track Active exploration of […]
20 implants of the Aeson® artificial heart performed in the first half of 2024 Pace of 4 implants per month in the second quarter Half-year sales at €3.2 million, higher than the 2023 full-year sales Unique safety and performance profile of Aeson® confirmed, based on more than 70 implants made since inception […]
